Kobayashi Pharmaceutical Co., Ltd.
KBYPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $166 | $173 | $166 | $155 |
| % Growth | -4.5% | 4.3% | 7.1% | – |
| Cost of Goods Sold | $78 | $77 | $74 | $66 |
| Gross Profit | $88 | $96 | $92 | $89 |
| % Margin | 52.9% | 55.6% | 55.5% | 57.2% |
| R&D Expenses | $9 | $9 | $8 | $8 |
| G&A Expenses | $5 | $30 | $5 | $5 |
| SG&A Expenses | $22 | $58 | $32 | $32 |
| Sales & Mktg Exp. | $17 | $28 | $27 | $27 |
| Other Operating Expenses | $32 | $4 | $26 | $23 |
| Operating Expenses | $63 | $71 | $66 | $63 |
| Operating Income | $25 | $26 | $27 | $26 |
| % Margin | 15% | 14.9% | 16% | 16.8% |
| Other Income/Exp. Net | -$11 | $2 | $1 | $2 |
| Pre-Tax Income | $14 | $28 | $28 | $28 |
| Tax Expense | $4 | $7 | $8 | $8 |
| Net Income | $10 | $20 | $20 | $20 |
| % Margin | 6.1% | 11.7% | 12% | 12.7% |
| EPS | 135.42 | 268.16 | 259.63 | 252.36 |
| % Growth | -49.5% | 3.3% | 2.9% | – |
| EPS Diluted | 135.42 | 268.16 | 259.59 | 252.36 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $8 | $6 | $5 | $5 |
| EBITDA | $22 | $34 | $32 | $31 |
| % Margin | 13.3% | 19.4% | 19.2% | 19.8% |